A phase I study to evaluate the safety and preliminary signs of efficacy of [177Lu]Lu-OncoFAP-23 alone and in combination with L19-IL2 as a treatment of metastatic FAP-positive solid tumors.

2023-509453-31-00 Protocol PH-FAPLU-02-23 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 11 Jun 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 4 sites · Protocol PH-FAPLU-02-23

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 56
Countries 1
Sites 4

Patients with advanced/metastatic FAP-positive tumors

Key facts

Sponsor
Philogen S.p.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
11 Jun 2025 → ongoing
Decision date (initial)
2024-09-18
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Patients with advanced/metastatic FAP-positive tumors

VersionLevelCodeTermSystem organ class
20.0 SOC 10029104 Neoplasms benign malignant and unspecified (incl cysts and polyps) 2

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Philogen S.p.A.

Sponsor organisation
Philogen S.p.A.
Address
Piazza La Lizza 7
City
Siena
Postcode
53100
Country
Italy

Scientific contact point

Organisation
Philogen S.p.A.
Contact name
Jacqueline Mock

Public contact point

Organisation
Philogen S.p.A.
Contact name
Jacqueline Mock

Locations

1 EU/EEA country · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Ongoing, recruiting 56 4
Rest of world 0

Investigational sites

Italy

4 sites · Ongoing, recruiting
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Medicina Nucleare, Via Mariano Semmola 52, 80131, Naples
Fondazione IRCCS Istituto Nazionale Dei Tumori
Diagnostic Imaging and Radiotherapy/Nuclear Medicine, Via Giacomo Venezian 1, 20133, Milan
Istituto Europeo Di Oncologia S.r.l.
Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative, Via Giuseppe Ripamonti 435, 20141, Milan
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
Department of Medicine and Surgery, Piazza Oms 1, 24127, Bergamo

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2025-06-11 2025-10-31

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-25 Italy Acceptable
2024-09-16
2024-09-18
2 SUBSTANTIAL MODIFICATION SM-1 2025-04-16 Italy Acceptable
2025-06-09
2025-06-20
3 SUBSTANTIAL MODIFICATION SM-2 2025-12-11 Italy Acceptable
2026-01-19
2026-02-10